Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar;40(3):677-691.
doi: 10.1111/jgh.16858. Epub 2025 Jan 8.

Probiotics Combined With Trimebutine for the Treatment of Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis

Qiu-Xiang Yu  1 , Dong-Dong Wang  2 , Peng-Ju Dong  2 , Li-Hua Zheng  1
Affiliations
Meta-Analysis

Probiotics Combined With Trimebutine for the Treatment of Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis

Qiu-Xiang Yu et al. J Gastroenterol Hepatol. 2025 Mar.

Abstract

Objective: This study aimed to assess the efficacy and safety of probiotics combined with trimebutine in the treatment of irritable bowel syndrome (IBS), addressing an important gap in current treatment strategies.

Methods: Randomized controlled trials (RCTs) of trimebutine combined with probiotics for the treatment of IBS were collected from various databases. All retrieved articles were screened and assessed for quality. The methodological quality of the included studies was assessed following the guidelines recommended by the Cochrane Collaboration. The meta-analysis of the included studies was conducted using RevMan 5.3 software.

Results: A total of 37 RCTs involving 4360 participants were included in this study. Among them, the treatment group consisted of 2177 participants, and the control group consisted of 2183 participants. The results showed that the overall efficacy of trimebutine combined with probiotics in the treatment of IBS was significantly higher than that of trimebutine alone (odds ratio [OR] = 5.09, 95 % confidence interval [CI] [4.19, 6.20], p < 0.00001). The effective rate in the combination therapy group was 93.5 % compared with 73.8 % in the trimebutine alone group. The safety profile was favorable, with adverse event rates of 1.75 % and 1.69 % in the combination and monotherapy groups, respectively. The most common adverse events were mild and included dry mouth, nausea and dizziness. No serious adverse events were reported in either group. Subgroup analysis based on the type of probiotic intervention showed that combination use was better than trimebutine alone, and the differences between each subgroup were statistically significant. Combination use of compound Lactobacillus capsules had the best effect (OR = 16.03, 95 % CI [4.57, 56.21], p < 0.0001]. These results highlight the potential role of strain-specific benefits in IBS treatment and suggest that probiotic strain selection may significantly influence treatment outcomes.

Conclusions: The combination of trimebutine and probiotics is more effective in the treatment of IBS compared with trimebutine alone.

Clinical trial registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42024516044.

Keywords: irritable bowel syndrome; meta‐analysis; probiotics; trimebutine.

PubMed Disclaimer

References

    1. I. Shaidullov, D. Bouchareb, D. Sorokina, and G. Sitdikova, “Nitric Oxide in the Mechanisms of Inhibitory Effects of Sodium Butyrate on Colon Contractions in a Mouse Model of Irritable Bowel Syndrome,” Naunyn‐Schmiedeberg's Archives of Pharmacology (2024), Epub ahead of print, https://doi.org/10.1007/s00210‐024‐03403‐1.
    1. E. Teasdale, H. Everitt, S. Alderson, et al., “Low‐Dose Amitriptyline for Irritable Bowel Syndrome (IBS): A Qualitative Study of Patients' and GPs' Views and Experiences,” British Journal of General Practice (2024), Epub ahead of print, https://doi.org/10.3399/BJGP.2024.0303.
    1. International EM, “Retracted: Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation‐Predominant Irritable Bowel Syndrome in the Elderly [retraction of: Emerg Med Int. 2022 Nov 11;2022:6125120],” Emergency Medicine International 2024 (2024): 9837328, https://doi.org/10.1155/2024/9837328.
    1. A. A. Makarova, G. M. Diukova, I. N. Ruchkina, et al., “Visceral Sensitivity in Diagnostics and Treatment of Severe Irritated Bowel Syndrome,” Terapevticheskiĭ Arkhiv 94, no. 2S (2022): 356–361, https://doi.org/10.26442/00403660.2022.02.201394.
    1. H. T. Lee and B. J. Kim, “Trimebutine as a Modulator of Gastrointestinal Motility,” Archives of Pharmacal Research 34, no. 6 (2011): 861–864, https://doi.org/10.1007/s12272‐011‐0600‐7.

MeSH terms

LinkOut - more resources